Arterial stiffness in chronic kidney disease: Causes and consequences

Heart

Volumn 96, Issue 11, 2010, Pages 817-823

  Chue, Colin D ^a   Townend, Jonathan N ^a   Steeds, Richard P ^a   Ferro, Charles J ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; GHRELIN; IMMUNOSUPPRESSIVE AGENT; MINERAL; PHOSPHATE BINDING AGENT; VITAMIN D;

ARTERIAL STIFFNESS; BLOOD VESSEL CALCIFICATION; BONE DISEASE; BONE METABOLISM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; COMPREHENSION; DEATH; DEVELOPED COUNTRY; DIET; ENDOTHELIAL DYSFUNCTION; EXTRACELLULAR MATRIX; HEART ARRHYTHMIA; HEART FAILURE; HEART FUNCTION; HEART VENTRICLE FUNCTION; HUMAN; MINERAL METABOLISM; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; POPULATION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ARTERIOSCLEROSIS; HUMANS; KIDNEY FAILURE, CHRONIC; RISK FACTORS;

EID: 77953713676     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2009.184879     Document Type: Review

References (100)

1. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305.
2. Van Biesen W, De Bacquer D, Verbeke F, et al. The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years. Eur Heart J 2007;28:478-83.
3. Keith DS, Nichols GA, Gullion CM, et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004;164:659-63.
4. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-47.
5. Baigent C, Landray M. Which cardiovascular risk factors matter in chronic kidney disease? Nephrol Dial Transplant 2007;22:9-11.
6. Strippoli GF, Craig JC, Schena FP. The number, quality, and coverage of randomized controlled trials in nephrology. J Am Soc Nephrol 2004;15:411-19.
7. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 2005;67:2089-100.
8. USRDS 2006 Annual data report. US renal data system. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2006.
9. Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States medicare population, 1998 to 1999. J Am Soc Nephrol 2005;16:489-95.
10. Edwards NC, Steeds RP, Ferro CJ, et al. The treatment of coronary artery disease in patients with chronic kidney disease. Qjm 2006;99:723-36.
11. Schwarz U, Buzello M, Ritz E, et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 2000;15:218-23. (Pubitemid 30064276)
12. van Popele NM, Grobbee DE, Bots ML, et al. Association between arterial stiffness and atherosclerosis: the rotterdam study. Stroke 2001;32:454-60.
13. Cecelja M, Chowienczyk P. Dissociation of aortic pulse wave velocity with risk factors for cardiovascular disease other than hypertension. a systematic review. Hypertension 2009;54:1328-36.
14. Avolio AP, Van Bortel LM, Boutouyrie P, et al. Role of pulse pressure amplification in arterial hypertension: experts' opinion and review of the data. Hypertension 2009;54:375-83.
15. Davies JE, Parker KH, Francis DP, et al. What is the role of the aorta in directing coronary blood flow? Heart 2008;94:1545-7.
16. Franklin SS, Gustin WT, Wong ND, et al. Hemodynamic patterns of age-related changes in blood pressure. The framingham heart study. Circulation 1997;96:308-15.
17. Baksi AJ, Treibel TA, Davies JE, et al. A Meta-analysis of the mechanism of blood pressure change with aging. J Am Coll Cardiol 2009;54:2087-92.
18. Wang JJ, O'Brien AB, Shrive NG, et al. Time-domain representation of ventricular-arterial coupling as a windkessel and wave system. Am J Physiol Heart Circ Physiol 2003;284:H1358-68.
19. O'Rourke MF, Safar ME. Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. Hypertension 2005;46:200-4.
20. London GM, Guerin AP, Marchais SJ, et al. Cardiac and arterial interactions in end-stage renal disease. Kidney Int 1996;50:600-8.
21. Saeki A, Recchia F, Kass DA. systolic flow augmentation in hearts ejecting into a model of stiff aging vasculature. Influence on myocardial perfusion-demand balance. Circ Res 1995;76:132-41.
22. Chen CH, Nakayama M, Nevo E, et al. Coupled systolic-ventricular and vascular stiffening with age: implications for pressure regulation and cardiac reserve in the elderly. J Am Coll Cardiol 1998;32:1221-7.
23. Watanabe H, Ohtsuka S, Kakihana M, et al. Coronary circulation in dogs with an experimental decrease in aortic compliance. J Am Coll Cardiol 1993;21:1497-506. (Pubitemid 23138723)
24. Davies JE, Whinnett ZI, Francis DP, et al. Evidence of a dominant backward-propagating "suction" wave responsible for diastolic coronary filling in humans, attenuated in left ventricular hypertrophy. Circulation 2006;113:1768-78.
25. Hundley WG, Kitzman DW, Morgan TM, et al. Cardiac cycle-dependent changes in aortic area and distensibility are reduced in older patients with isolated diastolic heart failure and correlate with exercise intolerance. J Am Coll Cardiol 2001;38:796-802.
26. Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995;47:186-92.
27. Edwards NC, Ferro CJ, Townend JN, et al. Aortic distensibility and arterial-ventricular coupling in early chronic kidney disease: a pattern resembling heart failure with preserved ejection fraction. Heart 2008;94:1038-43.
28. Edwards NC, Hirth A, Ferro CJ, et al. Subclinical abnormalities of left ventricular myocardial deformation in early-stage chronic kidney disease: the precursor of uremic cardiomyopathy? J Am Soc Echocardiogr 2008;21:1293-8.
29. Rakhit DJ, Zhang XH, Leano R, et al. Prognostic role of subclinical left ventricular abnormalities and impact of transplantation in chronic kidney disease. Am Heart J 2007;153:656-64.
30. Franklin SS, Jacobs MJ, Wong ND, et al. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension 2001;37:869-74.
31. Haider AW, Larson MG, Franklin SS, et al. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med 2003;138:10-16.
32. Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006;27: 2588-605.
33. Wang MC, Tsai WC, Chen JY, et al. Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease. Am J Kidney Dis 2005;45:494-501.
34. Greenwald SE. Ageing of the conduit arteries. J Pathol 2007;211:157-72.
35. Raveaud S, Mezin P, Lavanchy N, et al. Effects of chronic treatment with a low dose of nicorandil on the function of the rat aorta during ageing. Clin Exp Pharmacol Physiol 2009;36:988-94.
36. Dovinova I, Cacanyiova S, Faberova V, et al. The effect of an NO donor, pentaerythrityl tetranitrate, on biochemical, functional, and morphological attributes of cardiovascular system of spontaneously hypertensive rats. Gen Physiol Biophys 2009;28:86-93.
37. Amann K, Wolf B, Nichols C, et al. Aortic changes in experimental renal failure: hyperplasia or hypertrophy of smooth muscle cells? Hypertension 1997;29:770-5.
38. Jacob MP. Extracellular matrix remodeling and matrix metalloproteinases in the vascular wall during aging and in pathological conditions. Biomed Pharmacother 2003;57:195-202.
39. Chung AW, Yang HH, Radomski MW, et al. Long-term doxycycline is more effective than atenolol to prevent thoracic aortic aneurysm in marfan syndrome through the inhibition of matrix metalloproteinase-2 and -9. Circ Res 2008;102: e73-85.
40. Yasmin, McEniery CM, Wallace S, et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 2005;25:372.
41. Chung AW, Yang HH, Kim JM, et al. Upregulation of matrix metalloproteinase-2 in the arterial vasculature contributes to stiffening and vasomotor dysfunction in patients with chronic kidney disease. Circulation 2009;120:792-801.
42. Reiser K, McCormick RJ, Rucker RB. Enzymatic and nonenzymatic cross-linking of collagen and elastin. FASEB J 1992;6:2439-49.
43. Konova E, Baydanoff S, Atanasova M, et al. Age-related changes in the glycation of human aortic elastin. Exp Gerontol 2004;39:249-54.
44. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991;87:432-8.
45. Makita Z, Radoff S, Rayfield EJ, et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991;325:836-42.
46. Schwedler SB, Metzger T, Schinzel R, et al. Advanced glycation end products and mortality in hemodialysis patients. Kidney Int 2002;62:301-10.
47. Ueno H, Koyama H, Tanaka S, et al. Skin autofluorescence, a marker for advanced glycation end product accumulation, is associated with arterial stiffness in patients with end-stage renal disease. Metabolism 2008;57:1452-7.
48. Kass DA, Shapiro EP, Kawaguchi M, et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001;104:1464-70. (Pubitemid 32917336)
49. Zieman SJ, Melenovsky V, Clattenburg L, et al. Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. J Hypertens 2007;25:577-83.
50. McEniery CM, Wallace S, Mackenzie IS, et al. Endothelial function is associated with pulse pressure, pulse wave velocity, and augmentation index in healthy humans. Hypertension 2006;48:602-8.
51. Thambyrajah J, Landray MJ, McGlynn FJ, et al. Abnormalities of endothelial function in patients with predialysis renal failure. Heart 2000;83:205-9. (Pubitemid 30305552)
52. Vallance P, Leone A, Calver A, et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-5.
53. Bode-Boger SM, Scalera F, Kielstein JT, et al. Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol 2006;17:1128-34.
54. Zoccali C, Benedetto FA, Maas R, et al. Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol 2002;13:490-6.
55. Dhaun N, Goddard J, Webb DJ. The endothelin system and its antagonism in chronic kidney disease. J Am Soc Nephrol 2006;17:943-55.
56. Vuurmans TJ, Boer P, Koomans HA. Effects of endothelin-1 and endothelin-1 receptor blockade on cardiac output, aortic pressure, and pulse wave velocity in humans. Hypertension 2003;41:1253-8.
57. Dhaun N, Macintyre IM, Melville V, et al. Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease. Hypertension 2009;54:113-19.
58. Weber MA, Black H, Bakris G, et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 2009;374:1423-31.
59. Tepel M, van der Giet M, Statz M, et al. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 2003;107:992-5.
60. Wittstock A, Burkert M, Zidek W, et al. N-acetylcysteine improves arterial vascular reactivity in patients with chronic kidney disease. Nephron Clin Pract 2009;112: c184-9.
61. Peng X, Haldar S, Deshpande S, et al. Wall stiffness suppresses Akt/eNOS and cytoprotection in pulse-perfused endothelium. Hypertension 2003;41:378-81.
62. Tesauro M, Schinzari F, Rovella V, et al. Ghrelin restores the endothelin 1/nitric oxide balance in patients with obesity-related metabolic syndrome. Hypertension 2009;54:995-1000.
63. Maki-Petaja KM, Hall FC, Booth AD, et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation 2006;114:1185-92.
64. Cachofeiro V, Goicochea M, de Vinuesa SG, et al. Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int Suppl 2008;74:S4-9.
65. Yasmin, McEniery CM, Wallace S, et al. C-reactive protein is associated with arterial stiffness in apparently healthy individuals. Arterioscler Thromb Vasc Biol 2004;24:969-74.
66. Joly L, Djaballah W, Koehl G, et al. Aortic inflammation, as assessed by hybrid FDGPET/ CT imaging, is associated with enhanced aortic stiffness in addition to concurrent calcification. Eur J Nucl Med Mol Imaging 2009;36:979-85.
67. Choi HK, Hernan MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173-7.
68. Aikawa E, Aikawa M, Libby P, et al. Arterial and aortic valve calcification abolished by elastolytic cathepsin S deficiency in chronic renal disease. Circulation 2009;119: 1785-94.
69. Kranzhofer R, Schmidt J, Pfeiffer CA, et al. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999;19:1623-9. (Pubitemid 29323820)
70. Takagishi T, Murahashi N, Azagami S, et al. Effect of angiotensin II and thromboxane A2 on the production of matrix metalloproteinase by human aortic smooth muscle cells. Biochem Mol Biol Int 1995;35:265-73. (Pubitemid 26177794)
71. Ahimastos AA, Natoli AK, Lawler A, et al. Ramipril reduces large-artery stiffness in peripheral arterial disease and promotes elastogenic remodeling in cell culture. Hypertension 2005;45:1194-9.
72. Miyata T, van Ypersele de Strihou C, Ueda Y, et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol 2002;13:2478-87.
73. Mitchell GF, Dunlap ME, Warnica W, et al. Long-term trandolapril treatment is associated with reduced aortic stiffness: the prevention of events with angiotensin-converting enzyme inhibition hemodynamic substudy. Hypertension 2007;49: 1271-7.
74. Guerin AP, Blacher J, Pannier B, et al. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 2001;103:987-92. (Pubitemid 32183805)
75. Garg JP, Ellis R, Elliott WJ, et al. Angiotensin receptor blockade and arterial compliance in chronic kidney disease: a pilot study. Am J Nephrol 2005;25: 393-9.
76. Blacher J, Amah G, Girerd X, et al. Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. Am J Hypertens 1997;10:1326-34.
77. Lacolley P, Labat C, Pujol A, et al. Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone. Circulation 2002; 106:2848-53.
78. Brown NJ. Aldosterone and vascular inflammation. Hypertension 2008;51:161-7.
79. Ullian ME, Schelling JR, Linas SL. Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses. Hypertension 1992;20:67-73.
80. Lacolley P, Safar ME, Lucet B, et al. Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. J Am Coll Cardiol 2001;37:662-7.
81. Virdis A, Neves MF, Amiri F, et al. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 2002;40:504-10.
82. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996;98:1063-8. (Pubitemid 26293326)
83. Edwards NC, Steeds RP, Stewart PM, et al. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease. A randomized controlled trial. J Am Coll Cardiol 2009;54:505-12.
84. Balamuthusamy S, Srinivasan L, Verma M, et al. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis. Am Heart J 2008;155:791-805.
85. Safar ME, Thuilliez C, Richard V, et al. Pressure-independent contribution of sodium to large artery structure and function in hypertension. Cardiovasc Res 2000;46:269-76.
86. Oberleithner H, Riethmuller C, Schillers H, et al. Plasma sodium stiffens vascular endothelium and reduces nitric oxide release. Proc Natl Acad Sci U S A 2007;104:16281-6.
87. Gates PE, Tanaka H, Hiatt WR, et al. Dietary sodium restriction rapidly improves large elastic artery compliance in older adults with systolic hypertension. Hypertension 2004;44:35-41.
88. Ferro CJ, Chue CD, Steeds RP, et al. Is lowering phosphate exposure the key to preventing arterial stiffening with age? Heart 2009;95:1770-2.
89. Toussaint ND, Lau KK, Strauss BJ, et al. Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease. Nephrol Dial Transplant 2008;23:586-93.
90. London GM, Guerin AP, Marchais SJ, et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003;18:1731-40.
91. Jono S, McKee MD, Murry CE, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000;87:E10-7.
92. Chen NX, O'Neill KD, Duan D, et al. Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int 2002;62:1724-31.
93. Jono S, Ikari Y, Vermeer C, et al. Matrix Gla protein is associated with coronary artery calcification as assessed by electron-beam computed tomography. Thromb Haemost 2004;91:790-4.
94. Ketteler M, Bongartz P, Westenfeld R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003;361:827-33.
95. Adeney KL, Siscovick DS, Ix JH, et al. Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol 2009;20:381-7.
96. Shoji T, Shinohara K, Kimoto E, et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 2004;19:179-84.
97. Drissi H, Pouliot A, Koolloos C, et al. 1,25-(OH)2-vitamin D3 suppresses the bone-related Runx2/Cbfa1 gene promoter. Exp Cell Res 2002;274:323-33.
98. Rostand SG, Drueke TB. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 1999;56:383-92.
99. Connolly GM, Cunningham R, McNamee PT, et al. Elevated serum phosphate predicts mortality in renal transplant recipients. Transplantation 2009;87: 1040-4.
100. Amann K, Tornig J, Kugel B, et al. Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia. Kidney Int 2003;63: 1296-301.